The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
La Food and Drug Administration (FDA) des États-Unis a accordé jeudi une autorisation accélérée au nouveau médicament d'Amgen (AMGN), le tarlatamab, commercialisé sous le nom de marque Imdelltra, pour ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
Vendredi, les analystes d'Oppenheimer ont maintenu les perspectives positives d' Amgen Inc . (NASDAQ:AMGN), avec une réitération de la note "Outperform" et un objectif de prix stable de 380,00 $. Cet ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...
L'étude d'Amgen et d'AstraZeneca sur les maladies pulmonaires donne des résultats mitigés 20/05 MT Amgen annonce les résultats de l'essai COURSE de phase 2a évaluant Tezspire® (Tezepelumab ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
The rising usage of prescription/illicit drugs coupled with the increasing consumption of tobacco and alcohol is primarily ...
AbbVie ABBV dosed the first patient with ABBV-383, an investigational BCMA-CD3-targeted bispecific antibody, in the phase III ...
FRIDAY, May, 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab ...